A secondary RET mutation in the activation loop conferring resistance to vandetanibTakashi Nakaoku(National Cancer Centre Japan), Kōichi Goto(National Cancer Center Hospital East)Nature CommunicationsFebruary 6, 201810.1038/s41467-018-02994-7Cited by 106SaveCiteExport RISWatch citationsRelated PapersTrastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial|Journal of Clinical Oncology|2023|279